 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/39143
Commercial Opportunities in RNA Interference: The Emerging Revolution
|
Description: |
It is forecasted that the RNAi market will reach $185 million by 2008!
Considered the greatest molecular biology innovation of the last decade or two, RNA Interference (RNAi) has become a recognized functional genomics research tool for mammalian gene knock-down studies, target discovery, and validation and shows great therapeutic potential. The vast use for RNAi technology has motivated biotechnology and pharmaceutical companies, entrepreneurs, and venture capitalists to invest in the development and use of this technology. The market for RNAi is already expected to reach $38 million by the year's end.
This Commercial Opportunities in RNA Interference Market Analysis Report provides a thorough review of this promising technology. This Report will help you:
1. Pinpoint the market potential of RNAi with an examination of projected market impact through 2008.
2. Discover the competitive advantage of RNAi over comparable technologies, such as antisense, ribozymes, peptide nucleic acids, and morpholinos from a comprehensive review of the capabilities and limitations of both.
3. Identify commercial opportunities for utilizing related technologies to fully implement RNAi, including protein and phenotype profiling, through an assessment of their abilities.
4. Look inside the key RNAi industry players developing siRNA therapeutics, using siRna-mediated target validation, and specializing in siRNA and related reagents via detailed company profiles.
5. Learn about the patenting of RNAi with coverage of current patents and their holders.
6. Get an up-to-date technical review of RNAi through an evaluation of the latest developments, therapeutic breakthroughs, and uses of RNAi technologies. |
|
Contents: |
Executive Summary
Small Interference RNAs (siRNAs)
Introduction
Background of siRNAs
Discovery of RNAi
Current Frontier of Research in RNA
References
Market Drivers
Cost of Drug Development
Demand for High-Throughput Target Discovery
Demand for Target Validation
Demand for New Therapeutics
Diseases Ideal for siRNA Therapeutics
Cancer
Viral Infectious Disease
CNS Disease
Cardiovascular Disease
Other Indications
References
Other RNA Technology in Target Validation and Therapeutics
Antisense
Ribozyme
Aptamers
Peptide Nucleic Acids
Morpholinos
References
Other Rival Technologies in Target Validation
Gene Knock-Outs
Mice
Zebra Fish
References
Related Technologies Critical to High-Throughput Target Validation
Protein Profiling Technology
Cell Microarrays
Phenotype Profiling Technology
References
Profiles of Companies Developing siRNA Therapeutics
AGY Therapeutics
Alnylam Pharmaceutical
Antisense Therapeutics Ltd
Benitec Australia Ltd
Genta
Hemisperx Biopharma
International Therapeutics (HIV)
Intradigm
ISIS Pharmaceuticals
Noxxon Pharma
Nucleonics
Ribopharma AG
Sirna Therapeutics (formerly Ribozyme Pharmaceuticals)
Profiles of Companies Developing siRNA-Mediated Target Validation
Atugen AG
Cenix Bioscience GmbH
Compugen Ltd
deVGen NV
Immusol
Ingenium Pharmaceuticals AG
Lexicon Genetics
Phenomix Pharmaceutics
Phylonix Pharmaceuticals
Sequitur
Zygogen LLC
Profiles of Companies Specialized in siRNA and siRNA-Related Reagents
Allele Biotechnology and Pharmaceuticals
Amaxa GmbH
Ambion
Dharmacon
Eurogentec
Gene Therapy Systems
Imgenex
MWG Biotech AG
Mirus
Oligoengine
Polyplus-Transfection SAS
Proligo
Qiagen NV (Xeragon)
Trends
Strengths
Weaknesses
Opportunities
|
|
Companies Mentioned |
AGY Therapeutics
Alnylam Pharmaceutical
Antisense Therapeutics Ltd
Benitec Australia Ltd
Genta
Hemisperx Biopharma
International Therapeutics (HIV)
Intradigm
ISIS Pharmaceuticals
Noxxon Pharma
Nucleonics
Ribopharma AG
Sirna Therapeutics (formerly Ribozyme Pharmaceuticals) Companies Developing siRNA-Mediated Target Validation
Atugen AG
Cenix Bioscience GmbH
Compugen Ltd
deVGen NV
Immusol
Ingenium Pharmaceuticals AG
Lexicon Genetics
Phenomix Pharmaceutics
Phylonix Pharmaceuticals
Sequitur
Zygogen LLC Companies Specialized in siRNA and siRNA-Related Reagents
Allele Biotechnology and Pharmaceuticals
Amaxa GmbH
Ambion
Dharmacon
Eurogentec
Gene Therapy Systems
Imgenex
MWG Biotech AG
Mirus
Oligoengine
Polyplus-Transfection SAS
Proligo
Qiagen NV (Xeragon) |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/39143
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 05/09/2008 15:55:48 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Commercial Opportunities in RNA Interference: The Emerging Revolution
|
|
Web Address: |
http://www.researchandmarkets.com/reports/39143
|
|
Office Code: |
|
OCHHGKJRMPV
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic
|
|
€5,297.00
|
|
Electronic
- Site License
|
|
€7,415.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 05/09/2008 15:55:48
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
